Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
| 대상 질환 | Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | HonorHealth Research Institute |
| 상태 | 완료 |
| 참여자 수 | 19 명 |
| 중재(약물) | Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine |
| 시작일 | 2020년 12월 1일 |
| 완료일 | 2024년 2월 21일 |
| 결과 공개일 | 2026년 7월 21일 |
요약
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
CA 19-9 Normalization
| Treatment | 9.1 Percentage of participants |
|---|---|
| Treatment | 18.2 Percentage of participants |
| Treatment | 72.7 Percentage of participants |
| Treatment | 36.4 Percentage of participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group